Context Osteoporosis is associated with significant morbidity and mortality. Oral
bisphosphonates have become a mainstay of treatment, but concerns have emerged that …

Bisphosphonates are the primary therapy for postmenopausal and glucocorticoid‐induced
osteoporosis. Case series suggest a potential link between prolonged use of …

Oral bisphosphonates are first‐line therapy for the prevention and treatment of osteoporosis
in postmenopausal women. Although bisphosphonate treatment has been shown to reduce …

The development of bisphosphonate therapy represented an important advance in the
treatment of low bone mass and osteoporosis, conditions that affect more than half of …

Background Bisphosphonates are effective in reducing hip and osteoporotic fractures.
However, concerns about atypical femur fractures have contributed to substantially …

Based upon interest in a bisphosphonate drug holiday, we evaluate the risk for hip fracture
after bisphosphonate discontinuation. Among women compliant with bisphosphonates for≥ …

Recent evidence has linked long-term bisphosphonate use with insufficiency fractures of the
femur in postmenopausal women. In this case–control study, we have identified a significant …

Background A number of recent case reports and series have identified a subgroup of
atypical fractures of the femoral shaft associated with bisphosphonate use. A population …

Increasing numbers of atypical hip fractures have been reported among patients with
bisphosphonate use. However, the nature and extent of the problem are unknown despite …

Intravenous bisphosphonates reduce mortality following hip fracture. We determined
whether new use of oral bisphosphonates was also associated with reductions in mortality in …